Puma Biotechnology (PBYI) News Today $2.97 -0.05 (-1.66%) As of 01/17/2025 04:00 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 Time Period Is Now The Time To Put Puma Biotechnology (NASDAQ:PBYI) On Your Watchlist?January 17 at 8:14 PM | finance.yahoo.comResearch Analysts Set Expectations for PBYI FY2024 EarningsJanuary 14, 2025 | americanbankingnews.comZacks Research Issues Pessimistic Estimate for PBYI EarningsPuma Biotechnology, Inc. (NASDAQ:PBYI - Free Report) - Research analysts at Zacks Research reduced their FY2024 earnings per share (EPS) estimates for shares of Puma Biotechnology in a report released on Thursday, January 9th. Zacks Research analyst R. Department now forecasts that the biopharmacJanuary 13, 2025 | marketbeat.comEquities Analysts Set Expectations for PBYI FY2025 EarningsPuma Biotechnology, Inc. (NASDAQ:PBYI - Free Report) - Investment analysts at Zacks Research raised their FY2025 earnings per share (EPS) estimates for shares of Puma Biotechnology in a research report issued to clients and investors on Thursday, January 9th. Zacks Research analyst R. DepartmentJanuary 10, 2025 | marketbeat.comInsider Selling: Puma Biotechnology, Inc. (NASDAQ:PBYI) Insider Sells 9,437 Shares of StockJanuary 4, 2025 | insidertrades.comPuma Biotechnology, Inc. (NASDAQ:PBYI) Insider Jeffrey Jerome Ludwig Sells 9,437 SharesPuma Biotechnology, Inc. (NASDAQ:PBYI - Get Free Report) insider Jeffrey Jerome Ludwig sold 9,437 shares of the stock in a transaction that occurred on Thursday, January 2nd. The stock was sold at an average price of $3.15, for a total transaction of $29,726.55. Following the transaction, the insider now owns 108,951 shares in the company, valued at approximately $343,195.65. The trade was a 7.97 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.January 3, 2025 | marketbeat.comAlan H. Auerbach Sells 33,841 Shares of Puma Biotechnology, Inc. (NASDAQ:PBYI) StockPuma Biotechnology, Inc. (NASDAQ:PBYI - Get Free Report) CEO Alan H. Auerbach sold 33,841 shares of the stock in a transaction that occurred on Thursday, January 2nd. The stock was sold at an average price of $3.15, for a total value of $106,599.15. Following the sale, the chief executive officer now directly owns 7,029,674 shares in the company, valued at $22,143,473.10. This represents a 0.48 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.January 3, 2025 | marketbeat.comPuma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)January 3, 2025 | businesswire.comZacks Research Has Bullish Forecast for PBYI FY2025 EarningsPuma Biotechnology, Inc. (NASDAQ:PBYI - Free Report) - Stock analysts at Zacks Research upped their FY2025 earnings per share estimates for shares of Puma Biotechnology in a report issued on Tuesday, December 24th. Zacks Research analyst R. Department now expects that the biopharmaceutical companDecember 27, 2024 | marketbeat.comWith 49% stake, Puma Biotechnology, Inc. (NASDAQ:PBYI) seems to have captured institutional investors' interestDecember 23, 2024 | uk.finance.yahoo.comHC Wainwright Reiterates Buy Rating for Puma Biotechnology (NASDAQ:PBYI)HC Wainwright reissued a "buy" rating and issued a $7.00 price target on shares of Puma Biotechnology in a research report on Monday.December 23, 2024 | marketbeat.comPuma Biotechnology: Continuing To Push Their Aurora Kinase Story ForwardDecember 16, 2024 | seekingalpha.comPuma Biotechnology (NASDAQ:PBYI) Lowered to "Buy" Rating by StockNews.comStockNews.com lowered Puma Biotechnology from a "strong-buy" rating to a "buy" rating in a research note on Friday.December 6, 2024 | marketbeat.com3 Emerging Biotech Stocks Developing Breakthrough TherapiesDecember 5, 2024 | stocknews.comPuma Biotechnology (NASDAQ:PBYI) Downgraded by StockNews.com to BuyStockNews.com cut Puma Biotechnology from a "strong-buy" rating to a "buy" rating in a research note on Friday.November 23, 2024 | marketbeat.comPuma Biotechnology initiates ALISertib in CAncer trialNovember 20, 2024 | markets.businessinsider.comBuy Rating Reiterated for Puma Biotechnology Amid Promising Phase 2 Trial and Strategic FDA EngagementNovember 20, 2024 | markets.businessinsider.comLos Angeles Capital Management LLC Acquires Shares of 245,695 Puma Biotechnology, Inc. (NASDAQ:PBYI)Los Angeles Capital Management LLC purchased a new stake in Puma Biotechnology, Inc. (NASDAQ:PBYI - Free Report) during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 245,695 shares of the biopharmaceutical companyNovember 17, 2024 | marketbeat.comPuma Biotechnology Inc (PBYI) Q3 2024 Earnings Call Highlights: Revenue Surge and Strategic ...November 8, 2024 | finance.yahoo.comPuma Biotechnology Reports Strong Q3 2024 GrowthNovember 8, 2024 | markets.businessinsider.comBarclays Reaffirms Their Sell Rating on Puma Biotechnology (PBYI)November 8, 2024 | markets.businessinsider.comHC Wainwright Reaffirms Buy Rating for Puma Biotechnology (NASDAQ:PBYI)HC Wainwright restated a "buy" rating and issued a $7.00 target price on shares of Puma Biotechnology in a research note on Friday.November 8, 2024 | marketbeat.comQ3 2024 Puma Biotechnology Inc Earnings Call TranscriptNovember 8, 2024 | gurufocus.comPuma Biotechnology, Inc. (PBYI) Q3 2024 Earnings Conference Call TranscriptNovember 8, 2024 | seekingalpha.comPuma Biotechnology (NASDAQ:PBYI) Stock Rating Upgraded by StockNews.comStockNews.com raised Puma Biotechnology from a "buy" rating to a "strong-buy" rating in a research report on Friday.November 1, 2024 | marketbeat.comPuma Biotechnology (PBYI) Set to Announce Earnings on ThursdayPuma Biotechnology (NASDAQ:PBYI) will be releasing earnings after the market closes on Thursday, November 7, Zacks reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=335006)October 31, 2024 | marketbeat.comSHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Puma Biotechnology, Inc. (NASDAQ: PBYI) and Encourages Investors to Contact the FirmOctober 29, 2024 | globenewswire.comPuma Biotechnology to Host Conference Call to Discuss Third Quarter Financial ResultsOctober 25, 2024 | finance.yahoo.comPuma Biotechnology (NASDAQ:PBYI) Rating Increased to Strong-Buy at StockNews.comStockNews.com upgraded Puma Biotechnology from a "buy" rating to a "strong-buy" rating in a research note on Wednesday.October 23, 2024 | marketbeat.comZacks Research Has Positive Outlook for PBYI FY2026 EarningsPuma Biotechnology, Inc. (NASDAQ:PBYI - Free Report) - Stock analysts at Zacks Research upped their FY2026 earnings per share (EPS) estimates for Puma Biotechnology in a research note issued on Thursday, October 17th. Zacks Research analyst R. Department now anticipates that the biopharmaceuticalOctober 21, 2024 | marketbeat.comPuma Biotechnology IncOctober 18, 2024 | money.usnews.comQ3 EPS Estimate for Puma Biotechnology Increased by AnalystPuma Biotechnology, Inc. (NASDAQ:PBYI - Free Report) - Analysts at Zacks Research lifted their Q3 2026 earnings per share estimates for Puma Biotechnology in a research note issued on Thursday, October 17th. Zacks Research analyst R. Department now expects that the biopharmaceutical company willOctober 18, 2024 | marketbeat.comZacks Research Analysts Reduce Earnings Estimates for Puma Biotechnology, Inc. (NASDAQ:PBYI)Puma Biotechnology, Inc. (NASDAQ:PBYI - Free Report) - Equities researchers at Zacks Research reduced their FY2025 earnings per share (EPS) estimates for Puma Biotechnology in a research note issued on Thursday, September 26th. Zacks Research analyst R. Department now anticipates that the biopharSeptember 30, 2024 | marketbeat.comFrazier Life Sciences Management L.P. Purchases 246,264 Shares of Puma Biotechnology, Inc. (NASDAQ:PBYI)Frazier Life Sciences Management L.P. lifted its position in shares of Puma Biotechnology, Inc. (NASDAQ:PBYI - Free Report) by 8.7% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor ownedSeptember 29, 2024 | marketbeat.comAffinity Asset Advisors LLC Purchases Shares of 250,000 Puma Biotechnology, Inc. (NASDAQ:PBYI)Affinity Asset Advisors LLC purchased a new stake in shares of Puma Biotechnology, Inc. (NASDAQ:PBYI - Free Report) in the 2nd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 250,000 shares of the biopharmaceutical company's stock,September 25, 2024 | marketbeat.comPuma Biotechnology Inc (PBYI)September 18, 2024 | investing.comPuma Biotechnology to Present at the H.C. Wainwright 26th Annual Global Investment ConferenceSeptember 4, 2024 | finance.yahoo.comZacks Research Weighs in on Puma Biotechnology, Inc.'s Q1 2026 Earnings (NASDAQ:PBYI)Puma Biotechnology, Inc. (NASDAQ:PBYI - Free Report) - Equities researchers at Zacks Research increased their Q1 2026 earnings per share estimates for shares of Puma Biotechnology in a research note issued to investors on Wednesday, August 28th. Zacks Research analyst R. Department now forecastsSeptember 2, 2024 | marketbeat.comThe Future of Medicine: Key Biotech Stocks to WatchAugust 21, 2024 | theglobeandmail.comThe Future of Medicine: Key Biotech Stocks to Watch (OSTX, CRBP, PBYI, ATNM)August 21, 2024 | theglobeandmail.comPuma Biotech confirms court ruling on patent invalidity, disagrees with verdictAugust 15, 2024 | msn.comMichael Patrick Miller Sells 23,358 Shares of Puma Biotechnology, Inc. (NASDAQ:PBYI) StockAugust 15, 2024 | insidertrades.comPuma Biotechnology quickly drops after patents for Tagrisso ruled invalidAugust 14, 2024 | msn.comPuma Biotech drops after patents ruled invalid in fight with AstraZeneca over TagrissoAugust 14, 2024 | msn.comPuma Biotechnology, Inc. (NASDAQ:PBYI) Director Sells $81,519.42 in StockPuma Biotechnology, Inc. (NASDAQ:PBYI - Get Free Report) Director Michael Patrick Miller sold 23,358 shares of the company's stock in a transaction dated Monday, August 12th. The shares were sold at an average price of $3.49, for a total value of $81,519.42. Following the sale, the director now owns 47,000 shares in the company, valued at $164,030. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.August 13, 2024 | marketbeat.comPuma Biotechnology (NASDAQ:PBYI) Rating Lowered to Buy at StockNews.comStockNews.com cut shares of Puma Biotechnology from a "strong-buy" rating to a "buy" rating in a report on Tuesday.August 13, 2024 | marketbeat.comVanguard Group Inc. Reduces Holdings in Puma Biotechnology, Inc. (NASDAQ:PBYI)Vanguard Group Inc. lowered its holdings in shares of Puma Biotechnology, Inc. (NASDAQ:PBYI - Free Report) by 8.2% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 3,491,249 shares of the biopharmaceuticalAugust 12, 2024 | marketbeat.comPuma Biotechnology's (NASDAQ:PBYI) Earnings Offer More Than Meets The EyeAugust 9, 2024 | finance.yahoo.comPuma Biotechnology (NASDAQ:PBYI) Upgraded by StockNews.com to "Strong-Buy"StockNews.com upgraded shares of Puma Biotechnology from a "buy" rating to a "strong-buy" rating in a report on Monday.August 5, 2024 | marketbeat.comAnalysts Have Been Trimming Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target After Its Latest ReportAugust 3, 2024 | finance.yahoo.com Get Puma Biotechnology News Delivered to You Automatically Sign up to receive the latest news and ratings for PBYI and its competitors with MarketBeat's FREE daily newsletter. Email Address PBYI Media Mentions By Week PBYI Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. PBYI News Sentiment▼-0.100.44▲Average Medical News Sentiment PBYI News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. PBYI Articles This Week▼42▲PBYI Articles Average Week Get Puma Biotechnology News Delivered to You Automatically Sign up to receive the latest news and ratings for PBYI and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Autolus Therapeutics News Today Erasca News Today ORIC Pharmaceuticals News Today VectivBio News Today Tectonic Therapeutic News Today Kura Oncology News Today CARGO Therapeutics News Today Humacyte News Today Pharvaris News Today Annexon News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:PBYI) was last updated on 1/20/2025 by MarketBeat.com Staff From Our PartnersLast time you’ll see this priced at $1.00When was the last time you bought something for a buck? I don’t even think you can buy anything at McDonalds f...StocksToTrade | SponsoredKamala’s final humiliation The investments connected to Trump's second term in ways that almost nobody outside his inner circle is aware ...Porter & Company | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredThe #1 Stock for Trump’s Second Term?Imagine how much money you could make if you bought all of the top performing stocks during Trump's second ter...InvestorPlace | SponsoredGrab This Altcoin Before Trump's Crypto AnnouncementThe #1 Coin Poised to Soar Under Trump Pro-Crypto White House could make this the investment opportunity of...Crypto 101 Media | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredStunning Trump Exec Order LeakedThis secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Puma Biotechnology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Puma Biotechnology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
